Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab bridging maintenance after chemotherapy in intermediate-risk pediatric B-cell ALL (real-world study)
ChiCTR2300075198Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Relapse-free survival. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2300075198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075198.